Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Marmé F[au]:

Search results

Items: 1 to 50 of 160

1.

ASCO 2019: New Results in Breast Cancer.

Gluz O, Hartkopf A, Kümmel S, Marmé F.

Breast Care (Basel). 2019 Aug;14(4):256-258. doi: 10.1159/000501874. Epub 2019 Aug 6. No abstract available.

2.

Second breast conserving therapy after ipsilateral breast tumor recurrence - a 10-year experience of re-irradiation.

Forster T, Akbaba S, Schmitt D, Krug D, El Shafie R, Oelmann-Avendano J, Lindel K, König L, Arians N, Bernhardt D, Marmé F, Schneeweiss A, Heil J, Sohn C, Debus J, Hörner-Rieber J.

J Contemp Brachytherapy. 2019 Aug;11(4):312-319. doi: 10.5114/jcb.2019.87001. Epub 2019 Aug 29.

3.

Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.

Matulonis UA, Walder L, Nøttrup TJ, Bessette P, Mahner S, Gil-Martin M, Kalbacher E, Ledermann JA, Wenham RM, Woie K, Lau S, Marmé F, Casado Herraez A, Hardy-Bessard AC, Banerjee S, Lindahl G, Benigno B, Buscema J, Travers K, Guy H, Mirza MR.

J Clin Oncol. 2019 Sep 16:JCO1900917. doi: 10.1200/JCO.19.00917. [Epub ahead of print]

PMID:
31518175
4.

Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial.

Banys-Paluchowski M, Loibl S, Witzel I, Mundhenke C, Lederer B, Solbach C, Karn T, Marmé F, Nekljudova V, Schem C, Stickeler E, Willumsen N, Karsdal MA, Untch M, Müller V.

Cancers (Basel). 2019 Aug 15;11(8). pii: E1186. doi: 10.3390/cancers11081186.

5.

Fibroblast growth factor receptor 4 (FGFR4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancer.

Heublein S, Anglesio MS, Marmé F, Kommoss S.

J Cancer Res Clin Oncol. 2019 Sep;145(9):2251-2259. doi: 10.1007/s00432-019-02986-0. Epub 2019 Aug 5.

PMID:
31385026
6.

Extracapsular Lymph Node Involvement in Ovarian Carcinoma.

Heublein S, Schulz H, Marmé F, Angele M, Czogalla B, Burges A, Mahner S, Mayr D, Jeschke U, Schmoeckel E.

Cancers (Basel). 2019 Jul 1;11(7). pii: E924. doi: 10.3390/cancers11070924.

7.

Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS + EG score.

Michel LL, Sommer L, González Silos R, Lorenzo Bermejo J, von Au A, Seitz J, Hennigs A, Smetanay K, Golatta M, Heil J, Schütz F, Sohn C, Schneeweiss A, Marmé F.

Breast Cancer Res Treat. 2019 Sep;177(2):437-446. doi: 10.1007/s10549-019-05314-9. Epub 2019 Jun 24.

PMID:
31236813
8.

Preclinical evaluation of peptide-based radiotracers for integrin αvβ6-positive pancreatic carcinoma.

Müller M, Altmann A, Sauter M, Lindner T, Jäger D, Rathke H, Herold-Mende C, Marmé F, Babich J, Mier W, Haberkorn U.

Nuklearmedizin. 2019 Aug;58(4):309-318. doi: 10.1055/a-0894-4127. Epub 2019 May 10.

PMID:
31075798
9.

Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.

Noske A, Möbus V, Weber K, Schmatloch S, Weichert W, Köhne CH, Solbach C, Ingold Heppner B, Steiger K, Müller V, Fasching P, Karn T, van Mackelenbergh M, Marmé F, Schmitt WD, Schem C, Stickeler E, Loibl S, Denkert C.

Eur J Cancer. 2019 Jun;114:76-88. doi: 10.1016/j.ejca.2019.04.010. Epub 2019 May 7.

PMID:
31075727
10.

Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient.

Fremd C, Hlevnjak M, Zapatka M, Zoernig I, Halama N, Fejzibegovic N, Thewes V, Lichter P, Schirmacher P, Kloor M, Marmé F, Schütz F, Kosaloglu Z, Sinn HP, Jäger D, Schneeweiss A.

Breast Care (Basel). 2019 Mar;14(1):53-59. doi: 10.1159/000492580. Epub 2018 Nov 14.

PMID:
31019444
11.

Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).

Hauke J, Hahnen E, Schneider S, Reuss A, Richters L, Kommoss S, Heimbach A, Marmé F, Schmidt S, Prieske K, Gevensleben H, Burges A, Borde J, De Gregorio N, Nürnberg P, El-Balat A, Thiele H, Hilpert F, Altmüller J, Meier W, Dietrich D, Kimmig R, Schoemig-Markiefka B, Kast K, Braicu E, Baumann K, Jackisch C, Park-Simon TW, Ernst C, Hanker L, Pfisterer J, Schnelzer A, du Bois A, Schmutzler RK, Harter P.

J Med Genet. 2019 Sep;56(9):574-580. doi: 10.1136/jmedgenet-2018-105930. Epub 2019 Apr 12.

PMID:
30979843
12.

68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer.

Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Röhrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, Jäger D, Debus J, Haberkorn U, Giesel FL.

J Nucl Med. 2019 Jun;60(6):801-805. doi: 10.2967/jnumed.119.227967. Epub 2019 Apr 6.

PMID:
30954939
13.

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA).

Bischoff J, Barinoff J, Mundhenke C, Bauerschlag DO, Costa SD, Herr D, Lübbe K, Marmé F, Maass N, von Minckwitz G, Grischke EM, Müller V, Schmidt M, Gerber B, Kümmel S, Schumacher C, Krabisch P, Seiler S, Thill M, Nekljudova V, Loibl S.

Anticancer Drugs. 2019 Apr;30(4):394-401. doi: 10.1097/CAD.0000000000000722.

PMID:
30875348
14.

Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention.

Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, Debus J, Marmé F, Jäger D, Mier W, Haberkorn U.

J Nucl Med. 2019 Oct;60(10):1421-1429. doi: 10.2967/jnumed.118.224469. Epub 2019 Mar 8.

15.

Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study.

Mavratzas A, Baek S, Gerber B, Schmidt M, Moebus V, Foerster F, Grischke EM, Fasching P, Strumberg D, Solomayer E, Klare P, Windemuth-Kieselbach C, Hartmann S, Schneeweiss A, Marmé F.

Breast. 2019 Jun;45:22-28. doi: 10.1016/j.breast.2019.02.002. Epub 2019 Feb 13.

16.

Prediction of local recurrence risk after neoadjuvant chemotherapy in patients with primary breast cancer: Clinical utility of the MD Anderson Prognostic Index.

Michel LL, Sommer L, González Silos R, Lorenzo Bermejo J, von Au A, Seitz J, Hennigs A, Smetanay K, Golatta M, Heil J, Schütz F, Sohn C, Schneeweiss A, Marmé F.

PLoS One. 2019 Jan 31;14(1):e0211337. doi: 10.1371/journal.pone.0211337. eCollection 2019.

17.

Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer.

Heublein S, Page S, Mayr D, Schmoeckel E, Trillsch F, Marmé F, Mahner S, Jeschke U, Vattai A.

Int J Mol Sci. 2019 Jan 12;20(2). pii: E295. doi: 10.3390/ijms20020295.

18.

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial.

Hadji P, Stoetzer O, Decker T, Kurbacher CM, Marmé F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching PA, Lux MP, Lüftner D, Janni W, Muth M, Kreuzeder J, Quiering C, Grischke EM, Tesch H.

J Bone Oncol. 2018 Oct 2;14:010-10. doi: 10.1016/j.jbo.2018.09.010. eCollection 2019 Feb.

19.

What is the evidence for lymphadenectomy in presumed early ovarian cancer?

Schmalfeldt B, Brambs C, Burges A, El-Balat A, Emons G, Fink D, Fotopoulou C, Gropp-Meier M, Hanker LC, Harter P, Hasenburg A, Hauptmann S, Hilpert F, Kimmig R, Kommoss S, Kurzeder C, Mahner S, Marmé F, Mayr D, Meier W, Meinhold-Heerlein I, Mustea A, Ortmann O, Oskay-Özcelik G, Pfisterer J, Pölcher M, Runnebaum IB, Schröder W, Tanner B, Wagner U, Wimberger P, Sehouli J.

Arch Gynecol Obstet. 2019 Jan;299(1):1-5. doi: 10.1007/s00404-018-4945-8. No abstract available.

PMID:
30374648
20.

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial.

Stevic I, Müller V, Weber K, Fasching PA, Karn T, Marmé F, Schem C, Stickeler E, Denkert C, van Mackelenbergh M, Salat C, Schneeweiss A, Pantel K, Loibl S, Untch M, Schwarzenbach H.

BMC Med. 2018 Oct 10;16(1):179. doi: 10.1186/s12916-018-1163-y.

21.

Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer.

Jauch SF, Riethdorf S, Sprick MR, Schütz F, Schönfisch B, Brucker SY, Deutsch TM, Nees J, Saini M, Becker LM, Burwinkel B, Sinn P, Marmé F, Pantel K, Jäger D, Sohn C, Trumpp A, Wallwiener M, Schneeweiss A.

Breast Cancer Res Treat. 2019 Jan;173(1):155-165. doi: 10.1007/s10549-018-4972-y. Epub 2018 Oct 1.

PMID:
30276763
22.

COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer.

Smetanay K, Junio P, Feißt M, Seitz J, Hassel JC, Mayer L, Matthies LM, Schumann A, Hennigs A, Heil J, Sohn C, Jaeger D, Schneeweiss A, Marmé F.

Breast Cancer Res Treat. 2019 Jan;173(1):135-143. doi: 10.1007/s10549-018-4983-8. Epub 2018 Sep 25.

PMID:
30255454
23.

Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis: Results of the observational AGO-TR1 trial.

Weber-Lassalle K, Harter P, Hauke J, Ernst C, Kommoss S, Marmé F, Weber-Lassalle N, Prieske K, Dietrich D, Borde J, Pohl-Rescigno E, Reuss A, Ataseven B, Engel C, Stingl JC, Schmutzler RK, Hahnen E.

Hum Mutat. 2018 Dec;39(12):2040-2046. doi: 10.1002/humu.23653. Epub 2018 Oct 3.

PMID:
30216591
24.

TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer.

Heublein S, Friese K, Kost B, Marmé F, Kuhn C, Mahner S, Dannecker C, Mayr D, Jeschke U, Vattai A.

J Cancer Res Clin Oncol. 2018 Oct;144(10):1899-1907. doi: 10.1007/s00432-018-2706-5. Epub 2018 Jul 30.

PMID:
30062487
25.

Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.

Tesch H, Stoetzer O, Decker T, Kurbacher CM, Marmé F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching PA, Lux MP, Lüftner D, Hadji P, Janni W, Muth M, Kreuzeder J, Quiering C, Taran FA.

Int J Cancer. 2019 Feb 15;144(4):877-885. doi: 10.1002/ijc.31738. Epub 2018 Oct 30.

26.

Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies.

Schütz F, Marmé F, Domschke C, Sohn C, von Au A.

Breast Care (Basel). 2018 Mar;13(1):22-26. doi: 10.1159/000486330. Epub 2018 Jan 31. Review.

27.

Molecular Tumor Boards.

Rody A, Ettl J, Marmé F, Prat A.

Breast Care (Basel). 2018 Apr;13(2):141-143. doi: 10.1159/000489138. Epub 2018 Apr 23. No abstract available.

28.

Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.

Ghoussaini M, Edwards SL, Michailidou K, Nord S, Cowper-Sal Lari R, Desai K, Kar S, Hillman KM, Kaufmann S, Glubb DM, Beesley J, Dennis J, Bolla MK, Wang Q, Dicks E, Guo Q, Schmidt MK, Shah M, Luben R, Brown J, Czene K, Darabi H, Eriksson M, Klevebring D, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Lambrechts D, Thienpont B, Neven P, Wildiers H, Broeks A, Van't Veer LJ, Rutgers EJT, Couch FJ, Olson JE, Hallberg E, Vachon C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Peto J, Dos-Santos-Silva I, Gibson L, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Hall P, Li J, Liu J, Humphreys K, Kang D, Choi JY, Park SK, Noh DY, Matsuo K, Ito H, Iwata H, Yatabe Y, Guénel P, Truong T, Menegaux F, Sanchez M, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Benitez J, Pilar Zamora M, Perez JIA, Menéndez P, Shu XO, Lu W, Gao YT, Cai Q, Cox A, Cross SS, Reed MWR, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Lindblom A, Margolin S, Teo SH, Yip CH, Lee DSC, Wong TY, Hooning MJ, Martens JWM, Collée JM, van Deurzen CHM, Hopper JL, Southey MC, Tsimiklis H, Kapuscinski MK, Shen CY, Wu PE, Yu JC, Chen ST, Alnæs GG, Borresen-Dale AL, Giles GG, Milne RL, McLean C, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Hartman M, Miao H, Buhari SABS, Teo YY, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, García-Closas M, Figueroa J, Chanock SJ, Lissowska J, Simard J, Goldberg MS, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Brauch H, Brüning T, Koto YD, Radice P, Peterlongo P, Bonanni B, Volorio S, Dörk T, Bogdanova NV, Helbig S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Devilee P, Tollenaar RAEM, Seynaeve C, Van Asperen CJ, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Hamann U, Torres D, Zheng W, Long J, Anton-Culver H, Neuhausen SL, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, González-Neira A, Pita G, Rosario Alonso M, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, de Santiago I, Carroll J, Caldas C, Brown MA, Lupien M, Kristensen VN, Pharoah PDP, Chenevix-Trench G, French JD, Easton DF, Dunning AM.

Nat Commun. 2018 Apr 10;9:16193. doi: 10.1038/ncomms16193.

29.

Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor.

Loibl S, Weber K, Huober J, Krappmann K, Marmé F, Schem C, Engels K, Pfitzner BM, Kümmel S, Furlanetto J, Hartmann A, Darb-Esfahani S, Müller V, Staebler A, von Minckwitz G, Kronenwett R, Denkert C.

Clin Cancer Res. 2018 Jul 15;24(14):3358-3365. doi: 10.1158/1078-0432.CCR-17-2947. Epub 2018 Apr 4.

30.

Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.

Marmé F, Gomez-Roca C, Graudenz K, Huang F, Lettieri J, Peña C, Trnkova ZJ, Eucker J.

Cancer Chemother Pharmacol. 2018 Apr;81(4):727-737. doi: 10.1007/s00280-018-3540-9. Epub 2018 Feb 21.

PMID:
29468456
31.

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

Schneeweiss A, Park-Simon TW, Albanell J, Lassen U, Cortés J, Dieras V, May M, Schindler C, Marmé F, Cejalvo JM, Martinez-Garcia M, Gonzalez I, Lopez-Martin J, Welt A, Levy C, Joly F, Michielin F, Jacob W, Adessi C, Moisan A, Meneses-Lorente G, Racek T, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A.

Invest New Drugs. 2018 Oct;36(5):848-859. doi: 10.1007/s10637-018-0562-4. Epub 2018 Jan 19.

32.
33.

Body mass index and breast cancer survival: a Mendelian randomization analysis.

Guo Q, Burgess S, Turman C, Bolla MK, Wang Q, Lush M, Abraham J, Aittomäki K, Andrulis IL, Apicella C, Arndt V, Barrdahl M, Benitez J, Berg CD, Blomqvist C, Bojesen SE, Bonanni B, Brand JS, Brenner H, Broeks A, Burwinkel B, Caldas C, Campa D, Canzian F, Chang-Claude J, Chanock SJ, Chin SF, Couch FJ, Cox A, Cross SS, Cybulski C, Czene K, Darabi H, Devilee P, Diver WR, Dunning AM, Earl HM, Eccles DM, Ekici AB, Eriksson M, Evans DG, Fasching PA, Figueroa J, Flesch-Janys D, Flyger H, Gapstur SM, Gaudet MM, Giles GG, Glendon G, Grip M, Gronwald J, Haeberle L, Haiman CA, Hall P, Hamann U, Hankinson S, Hartikainen JM, Hein A, Hiller L, Hogervorst FB, Holleczek B, Hooning MJ, Hoover RN, Humphreys K, Hunter DJ, Hüsing A, Jakubowska A, Jukkola-Vuorinen A, Kaaks R, Kabisch M, Kataja V; kConFab/AOCS Investigators, Knight JA, Koppert LB, Kosma VM, Kristensen VN, Lambrechts D, Le Marchand L, Li J, Lindblom A, Lindström S, Lissowska J, Lubinski J, Machiela MJ, Mannermaa A, Manoukian S, Margolin S, Marme F, Martens JWM, McLean C, Menéndez P, Milne RL, Marie Mulligan A, Muranen TA, Nevanlinna H, Neven P, Nielsen SF, Nordestgaard BG, Olson JE, Perez JIA, Peterlongo P, Phillips KA, Poole CJ, Pylkäs K, Radice P, Rahman N, Rüdiger T, Rudolph A, Sawyer EJ, Schumacher F, Seibold P, Seynaeve C, Shah M, Smeets A, Southey MC, Tollenaar RAEM, Tomlinson I, Tsimiklis H, Ulmer HU, Vachon C, van den Ouweland AMW, Van't Veer LJ, Wildiers H, Willett W, Winqvist R, Zamora MP, Chenevix-Trench G, Dörk T, Easton DF, García-Closas M, Kraft P, Hopper JL, Zheng W, Schmidt MK, Pharoah PDP.

Int J Epidemiol. 2017 Dec 1;46(6):1814-1822. doi: 10.1093/ije/dyx131.

34.

Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.

Villegas SL, Darb-Esfahani S, von Minckwitz G, Huober J, Weber K, Marmé F, Furlanetto J, Schem C, Pfitzner BM, Lederer B, Engels K, Kümmel S, Müller V, Mehta K, Denkert C, Loibl S.

Breast Cancer Res Treat. 2018 Feb;168(1):179-187. doi: 10.1007/s10549-017-4581-1. Epub 2017 Nov 25.

PMID:
29177689
35.

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).

Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, Kimmig R, Kast K, Sehouli J, Baumann K, Jackisch C, Park-Simon TW, Hanker L, Kröber S, Pfisterer J, Gevensleben H, Schnelzer A, Dietrich D, Neunhöffer T, Krockenberger M, Brucker SY, Nürnberg P, Thiele H, Altmüller J, Lamla J, Elser G, du Bois A, Hahnen E, Schmutzler R.

PLoS One. 2017 Oct 20;12(10):e0186043. doi: 10.1371/journal.pone.0186043. eCollection 2017.

36.

A low-frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early-onset breast cancer (<60 years) and is associated with reduced DNA repair capacity.

Surowy H, Varga D, Burwinkel B, Marmé F, Sohn C, Luedeke M, Rinckleb A, Maier C, Deissler H, Volcic M, Wiesmüller L, Hasenburg A, Klar M, Hoegel J, Vogel W.

Int J Cancer. 2018 Feb 15;142(4):757-768. doi: 10.1002/ijc.31105. Epub 2017 Oct 30.

37.

The G protein-coupled estrogen receptor (GPER/GPR30) may serve as a prognostic marker in early-stage cervical cancer.

Friese K, Kost B, Vattai A, Marmé F, Kuhn C, Mahner S, Dannecker C, Jeschke U, Heublein S.

J Cancer Res Clin Oncol. 2018 Jan;144(1):13-19. doi: 10.1007/s00432-017-2510-7. Epub 2017 Sep 18.

PMID:
28924735
38.

Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.

van Mackelenbergh MT, Denkert C, Nekljudova V, Karn T, Schem C, Marmé F, Stickeler E, Jackisch C, Hanusch C, Huober J, Fasching PA, Blohmer JU, Kümmel S, Müller V, Schneeweiss A, Untch M, von Minckwitz G, Weber KE, Loibl S.

Breast Cancer Res Treat. 2018 Jan;167(1):59-71. doi: 10.1007/s10549-017-4480-5. Epub 2017 Sep 5.

PMID:
28875243
39.

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.

van Rossum AGJ, Schouten PC, Weber KE, Nekljudova V, Denkert C, Solbach C, Köhne CH, Thomssen C, Forstbauer H, Hoffmann G, Kohls A, Schmatloch S, Schem C, von Minckwitz G, Karn T, Möbus VJ, Linn SC, Loibl S, Marmé F.

Breast Cancer Res Treat. 2017 Dec;166(3):775-785. doi: 10.1007/s10549-017-4444-9. Epub 2017 Aug 18.

PMID:
28822007
40.

CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer.

Ettl J, Huober J, Lüftner D, Marmé F, Würstlein R.

Breast Care (Basel). 2017 May;12(2):118-120. doi: 10.1159/000475541. Epub 2017 Apr 26. No abstract available.

41.

The impact of human adipose tissue-derived stem cells on breast cancer cells: implications for cell-assisted lipotransfers in breast reconstruction.

Koellensperger E, Bonnert LC, Zoernig I, Marmé F, Sandmann S, Germann G, Gramley F, Leimer U.

Stem Cell Res Ther. 2017 May 25;8(1):121. doi: 10.1186/s13287-017-0579-1.

42.

Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.

Dinkic C, Eichbaum M, Schmidt M, Grischke EM, Gebauer G, Fricke HC, Lenz F, Wallwiener M, Marme F, Schneeweiss A, Sohn C, Rom J.

Gynecol Oncol. 2017 Aug;146(2):279-284. doi: 10.1016/j.ygyno.2017.05.013. Epub 2017 May 19.

PMID:
28528917
43.

The association between breast cancer and S100P methylation in peripheral blood by multicenter case-control studies.

Yang R, Stöcker S, Schott S, Heil J, Marme F, Cuk K, Chen B, Golatta M, Zhou Y, Sutter C, Wappenschmidt B, Schmutzler R, Bugert P, Qu B, Bartram CR, Sohn C, Schneeweiss A, Burwinkel B.

Carcinogenesis. 2017 Mar 1;38(3):312-320. doi: 10.1093/carcin/bgx004.

PMID:
28426874
44.

BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer.

Shimelis H, Mesman RLS, Von Nicolai C, Ehlen A, Guidugli L, Martin C, Calléja FMGR, Meeks H, Hallberg E, Hinton J, Lilyquist J, Hu C, Aalfs CM, Aittomäki K, Andrulis I, Anton-Culver H, Arndt V, Beckmann MW, Benitez J, Bogdanova NV, Bojesen SE, Bolla MK, Borresen-Dale AL, Brauch H, Brennan P, Brenner H, Broeks A, Brouwers B, Brüning T, Burwinkel B, Chang-Claude J, Chenevix-Trench G, Cheng CY, Choi JY, Collée JM, Cox A, Cross SS, Czene K, Darabi H, Dennis J, Dörk T, Dos-Santos-Silva I, Dunning AM, Fasching PA, Figueroa J, Flyger H, García-Closas M, Giles GG, Glendon G, Guénel P, Haiman CA, Hall P, Hamann U, Hartman M, Hogervorst FB, Hollestelle A, Hopper JL, Ito H, Jakubowska A, Kang D, Kosma VM, Kristensen V, Lai KN, Lambrechts D, Marchand LL, Li J, Lindblom A, Lophatananon A, Lubinski J, Machackova E, Mannermaa A, Margolin S, Marme F, Matsuo K, Miao H, Michailidou K, Milne RL, Muir K, Neuhausen SL, Nevanlinna H, Olson JE, Olswold C, Oosterwijk JJC, Osorio A, Peterlongo P, Peto J, Pharoah PDP, Pylkäs K, Radice P, Rashid MU, Rhenius V, Rudolph A, Sangrajrang S, Sawyer EJ, Schmidt MK, Schoemaker MJ, Seynaeve C, Shah M, Shen CY, Shrubsole M, Shu XO, Slager S, Southey MC, Stram DO, Swerdlow A, Teo SH, Tomlinson I, Torres D, Truong T, van Asperen CJ, van der Kolk LE, Wang Q, Winqvist R, Wu AH, Yu JC, Zheng W, Zheng Y, Leary J, Walker L, Foretova L, Fostira F, Claes KBM, Varesco L, Moghadasi S, Easton DF, Spurdle A, Devilee P, Vrieling H, Monteiro ANA, Goldgar DE, Carreira A, Vreeswijk MPG, Couch FJ; for kConFab/AOCS Investigators; for NBCS Collaborators.

Cancer Res. 2017 Jun 1;77(11):2789-2799. doi: 10.1158/0008-5472.CAN-16-2568. Epub 2017 Mar 10.

45.

Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.

Sinn HP, Schneeweiss A, Keller M, Schlombs K, Laible M, Seitz J, Lakis S, Veltrup E, Altevogt P, Eidt S, Wirtz RM, Marmé F.

BMC Cancer. 2017 Feb 13;17(1):124. doi: 10.1186/s12885-017-3111-1.

46.

Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade.

Hennigs A, Riedel F, Marmé F, Sinn P, Lindel K, Gondos A, Smetanay K, Golatta M, Sohn C, Schuetz F, Heil J, Schneeweiss A.

Breast Cancer Res Treat. 2016 Dec;160(3):491-499. doi: 10.1007/s10549-016-4016-4. Epub 2016 Oct 15.

47.

Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21.

Hamdi Y, Soucy P, Adoue V, Michailidou K, Canisius S, Lemaçon A, Droit A, Andrulis IL, Anton-Culver H, Arndt V, Baynes C, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Borresen-Dale AL, Brand JS, Brauch H, Brenner H, Broeks A, Burwinkel B, Chang-Claude J; NBCS Collaborators, Couch FJ, Cox A, Cross SS, Czene K, Darabi H, Dennis J, Devilee P, Dörk T, Dos-Santos-Silva I, Eriksson M, Fasching PA, Figueroa J, Flyger H, García-Closas M, Giles GG, Goldberg MS, González-Neira A, Grenaker-Alnæs G, Guénel P, Haeberle L, Haiman CA, Hamann U, Hallberg E, Hooning MJ, Hopper JL, Jakubowska A, Jones M, Kabisch M, Kataja V, Lambrechts D, Le Marchand L, Lindblom A, Lubinski J, Mannermaa A, Maranian M, Margolin S, Marme F, Milne RL, Neuhausen SL, Nevanlinna H, Neven P, Olswold C, Peto J, Plaseska-Karanfilska D, Pylkäs K, Radice P, Rudolph A, Sawyer EJ, Schmidt MK, Shu XO, Southey MC, Swerdlow A, Tollenaar RA, Tomlinson I, Torres D, Truong T, Vachon C, Van Den Ouweland AM, Wang Q, Winqvist R; kConFab/AOCS Investigators, Zheng W, Benitez J, Chenevix-Trench G, Dunning AM, Pharoah PD, Kristensen V, Hall P, Easton DF, Pastinen T, Nord S, Simard J.

Oncotarget. 2016 Dec 6;7(49):80140-80163. doi: 10.18632/oncotarget.12818.

48.

Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.

Furlanetto J, Eiermann W, Marmé F, Reimer T, Reinisch M, Schmatloch S, Stickeler E, Thomssen C, Untch M, Denkert C, von Minckwitz G, Lederer B, Nekljudova V, Weber K, Loibl S, Möbus V.

Ann Oncol. 2016 Nov;27(11):2053-2059. Epub 2016 Aug 8.

PMID:
27502721
49.

Genetic modifiers of CHEK2*1100delC-associated breast cancer risk.

Muranen TA, Greco D, Blomqvist C, Aittomäki K, Khan S, Hogervorst F, Verhoef S, Pharoah PDP, Dunning AM, Shah M, Luben R, Bojesen SE, Nordestgaard BG, Schoemaker M, Swerdlow A, García-Closas M, Figueroa J, Dörk T, Bogdanova NV, Hall P, Li J, Khusnutdinova E, Bermisheva M, Kristensen V, Borresen-Dale AL, Investigators N, Peto J, Dos Santos Silva I, Couch FJ, Olson JE, Hillemans P, Park-Simon TW, Brauch H, Hamann U, Burwinkel B, Marme F, Meindl A, Schmutzler RK, Cox A, Cross SS, Sawyer EJ, Tomlinson I, Lambrechts D, Moisse M, Lindblom A, Margolin S, Hollestelle A, Martens JWM, Fasching PA, Beckmann MW, Andrulis IL, Knight JA, Investigators K, Anton-Culver H, Ziogas A, Giles GG, Milne RL, Brenner H, Arndt V, Mannermaa A, Kosma VM, Chang-Claude J, Rudolph A, Devilee P, Seynaeve C, Hopper JL, Southey MC, John EM, Whittemore AS, Bolla MK, Wang Q, Michailidou K, Dennis J, Easton DF, Schmidt MK, Nevanlinna H.

Genet Med. 2017 May;19(5):599-603. doi: 10.1038/gim.2016.147. Epub 2016 Oct 6.

50.

Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation.

Ghoussaini M, French JD, Michailidou K, Nord S, Beesley J, Canisus S, Hillman KM, Kaufmann S, Sivakumaran H, Moradi Marjaneh M, Lee JS, Dennis J, Bolla MK, Wang Q, Dicks E, Milne RL, Hopper JL, Southey MC, Schmidt MK, Broeks A, Muir K, Lophatananon A, Fasching PA, Beckmann MW, Fletcher O, Johnson N, Sawyer EJ, Tomlinson I, Burwinkel B, Marme F, Guénel P, Truong T, Bojesen SE, Flyger H, Benitez J, González-Neira A, Alonso MR, Pita G, Neuhausen SL, Anton-Culver H, Brenner H, Arndt V, Meindl A, Schmutzler RK, Brauch H, Hamann U, Tessier DC, Vincent D, Nevanlinna H, Khan S, Matsuo K, Ito H, Dörk T, Bogdanova NV, Lindblom A, Margolin S, Mannermaa A, Kosma VM; kConFab/AOCS Investigators, Wu AH, Van Den Berg D, Lambrechts D, Floris G, Chang-Claude J, Rudolph A, Radice P, Barile M, Couch FJ, Hallberg E, Giles GG, Haiman CA, Le Marchand L, Goldberg MS, Teo SH, Yip CH, Borresen-Dale AL; NBCS Collaborators, Zheng W, Cai Q, Winqvist R, Pylkäs K, Andrulis IL, Devilee P, Tollenaar RA, García-Closas M, Figueroa J, Hall P, Czene K, Brand JS, Darabi H, Eriksson M, Hooning MJ, Koppert LB, Li J, Shu XO, Zheng Y, Cox A, Cross SS, Shah M, Rhenius V, Choi JY, Kang D, Hartman M, Chia KS, Kabisch M, Torres D, Luccarini C, Conroy DM, Jakubowska A, Lubinski J, Sangrajrang S, Brennan P, Olswold C, Slager S, Shen CY, Hou MF, Swerdlow A, Schoemaker MJ, Simard J, Pharoah PD, Kristensen V, Chenevix-Trench G, Easton DF, Dunning AM, Edwards SL.

Am J Hum Genet. 2016 Oct 6;99(4):903-911. doi: 10.1016/j.ajhg.2016.07.017. Epub 2016 Sep 15.

Supplemental Content

Support Center